SavedAdd your journal

Journals / Klinik Psikofarmakoloji Bülteni / 2011 / Cilt: 21 - Sayı: 3

Antidepressant drugs and risk of venous thromboembolism: A case report and literature review

Haixia ZHOU
Yongjiang TANG
Yu YAN
Qun Yİ
Xinmiao DU
Zongan LİANG
Pages
237–241
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As a result, a possible association was indeed found between the two, but no conclusion could be drawn.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Venous thromboembolism (VTE), including pulmonary thromboembolism (PTE) and deep venous thrombosis (DVT), is a common disease with a considerably high morbidity and mortality.
📊
Key Findings & Data:Mirtazapine, a novel antidepressant with a unique mode of action, is currently widely used in psychiatric practice.
💡
Conclusion & Impact:As a result, a possible association was indeed found between the two, but no conclusion could be drawn.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Venous thromboembolism (VTE), including pulmonary thromboembolism (PTE) and deep venous thrombosis (DVT), is a common disease with a considerably high morbidity and mortality. Mirtazapine, a novel antidepressant with a unique mode of action, is currently widely used in psychiatric practice. Preliminary clinical studies have showed that it is an effective and fast-acting antidepressant with few side effects. Reports about mirtazapine inducing VTE are rare. We present a case of VTE in a woman with depression without any major risk factors for thrombosis where mirtazapine was suspected to be the major associated factor in the development of VTE. In addition, we reviewed the literature to further explore the association between antidepressant drug use and the risk of VTE. As a result, a possible association was indeed found between the two, but no conclusion could be drawn.

🔖

Cite This Article

ZHOU, H., TANG, Y., YAN, Y., Yİ, Q., DU, X., LİANG, Z. (2022). Antidepressant drugs and risk of venous thromboembolism: A case report and literature review. Klinik Psikofarmakoloji Bülteni, Cilt: 21 - Sayı: 3, 237–241. https://ajindex.com/articles/574152

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Wang C. Pulmonary thromboembolism. In Textbook of Internal Medicine, Lu ZY, Zhong NS (editors). seventh ed., Beijing: People’s Medical Publishing House, 2008: p.79-87
  2. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353 (9162):1386-9
  3. Kroegel C, Reissig A. Principle mechanisms underlying venous thromboembolism: epidemiology, risk factors, pathophysiology and pathogenesis. Respiration 2003;70(1): 7-30
  4. Anderson F, Spencer F. Risk factors for venous thromboembolism. Circulation 2003;107 (23 Suppl 1):9-16
  5. Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ 2010;341:4245
  6. Zornberg GL, Jick H. Antipsychotic drug use and risk of firsttime idiopathic venous thromboembolism: a case-control study. Lancet 2000;356 (9237):1219-23
  7. Waage IM, Gedde-Dahl A. Pulmonary embolism possibly associated with olanzapine treatment. BMJ 2003;327(7428):1384
  8. Liperoti R, Pedone C, Lapane KL, Mor V, Bernabei R, Gambassi G. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med 2005;165(22):2677-82
  9. Burrows GD, Kremer CM. Mirtazapine: Clinical advantages in the treatment of depression. J Clin Psychopharmacol 1997;17(2): 34-9
  10. Remeron [package insert]. Nanjing, China: Organon; 2006
  11. Barbuto J. Preventing sudden death during a catatonic episode. Hosp Community Psychiatry 1983;34(1):72-3
  12. Kallner G, Lindelius R, Petterson U, Stockman O, Tham A. Mortalityin 497 patients with affective disorders attending a lithium clinic or after having left it. Pharmacopsychiatry 2000;33(1):8-13
  13. Thomassen R, Vandenbrouke JP, Rosendaal FR. Antipsychotic medications and venous thromboembolism. Br J Psychiatry 2001;179:63-6
  14. Parkin L, Skegg DC, Herbison GP, Paul C. Psychotic drugs and fatal pulmonary embolism. Pharmacoepidemiol Drug Saf 2003;12(8):647-52
  15. Lacut K, Le Gal G, Couturaud F, Cornily G, Leroyer C, Mottier D, et al.Association between antipsychotic drugs, antidepressant drugs and venousthromboembolism: results from the EDITH case-control study. Fundam Clin Pharmacol 2007;21(6):643-50
  16. Ray JG, Mamdani MM, Yeo EL. Antipsychotic and antidepressant drug use in the elderly and the risk of venous thromboembolism. Thromb Haemost 2002;88(2):205-9
  17. Jick SS, Li L. Antidepressant use and risk of v